## Edgar Filing: Truitt Joseph - Form 4

Truitt Josep Form 4										
January 07, FORN Check t if no lon subject Section Form 4 Form 5 obligati may con <i>See</i> Inst 1(b).	<b>M 4</b> UNITED his box to 16. or Section 17(	ED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 TEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES pursuant to Section 16(a) of the Securities Exchange Act of 1934, 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							PPROVAL 3235-0287 January 31, 2005 average urs per . 0.5	
(Print or Type Responses) 1. Name and Address of Reporting Person <u>*</u> Truitt Joseph (Last) (First) (Middle) C/O ACHILLION PHARMACEUTICALS, 300 CEODOE STREET			<ol> <li>Issuer Name and Ticker or Trading Symbol</li> <li>ACHILLION</li> <li>PHARMACEUTICALS INC</li> <li>[ACHN]</li> <li>Date of Earliest Transaction</li> <li>(Month/Day/Year)</li> <li>01/05/2009</li> </ol>				5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title 0ther (specify below) VP, Chief Commercial Officer			
(City)	(State)	(Zip)	Tab	ole I - Non-I	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Date 2A. Deemed		3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3,	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect	
Reminder: Re	port on a separate line	e for each cla	ass of sec	urities benef	Perso inforr requi	ons who res nation cont red to respo	or indirectly. spond to the colle ained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	

number. Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(*e.g.*, puts, calls, warrants, options, convertible securities)

## Edgar Filing: Truitt Joseph - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, any (Month/Day/Yea	Code	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount Number Shares	
Employee Stock Option (Right to Buy)	\$ 0.82	01/05/2009		А	100,000		<u>(1)</u>	01/05/2019	Common Stock	100,00	
Reporting Owners											
<b>Reporting Owner Name / Address</b>			Relationships								
			Director	10% Owner	Officer		Other				

Truitt Joseph C/O ACHILLION PHARMACEUTICALS **300 GEORGE STREET** NEW HAVEN, CT 06511

VP, Chief Commercial Officer

## Signatures

/s/ Mary Kay Fenton, Attorney 01/07/2009 in fact Date

\*\*Signature of Reporting Person

## **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The option grant vests as to 25% of the shares on the first anniversary of the date of grant and as to an additional 6.25% at the end of each (1) three month period thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.